Biotech Values

[mcbio]

New ENTA slide set:

Is there a specific reason why the big anti-viral players (GILD, GSK, etc.) haven't developed any RSV treatment (beyond the vaccines)? You would think that this would be a lucrative enough opportunity and they would have at least tried over the years. Perhaps they have, I just don't know the full back-story on attempted anti-RSV drugs over the years. Or perhaps not as lucrative an opportunity to the bigger players because a good portion get the vaccine and not as much of a need for an active treatment against RSV?